Whopping Mortality Benefit in Severe COVID Trial - Medpage Today

Oral sabizabulin showed 55% reduction in risk for death in hospitalized patients

Treatment with a novel, oral microtubule disruptor significantly reduced the risk of death in hospitalized COVID-19 patients with severe disease, an interim analysis of a phase III study indicated. … [+4908 chars]

full article...